V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC Mechanism of Action and Half-Life
CJC-1295 DACMechanism

CJC-1295 DAC Mechanism of Action and Half-Life

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does CJC-1295 with DAC act at the GHRH receptor? The peptide is a stabilized GHRH(1-29) analog that binds the pituitary GHRH receptor, a seven-transmembrane G-protein-coupled receptor needed for somatotroph proliferation and GH synthesis and secretion. The DAC (drug affinity complex) is a maleimide linker that bonds covalently to Cys34 of serum albumin, so the receptor-active peptide persists for far longer than native GHRH, which is inactivated within minutes. The mechanism has two layers: receptor signaling, which is the same as for other GHRH analogs, and carrier-mediated persistence, which changes the time profile of exposure. This is a laboratory-research explainer with no handling or amount instructions. For laboratory research use only.

The phrase "drug affinity complex" is often presented as if it were a separate pharmacological action. It is not. CJC-1295 with DAC acts at the same receptor as every other GHRH analog; what the DAC changes is how long the receptor-active peptide remains available. Keeping those two layers apart makes the literature easier to read, because many apparent disagreements between studies are differences in exposure time, not in receptor biology. This article separates the layers, describes the receptor and feedback context in which the signal is read, and lists the experimental readouts that distinguish them. It concerns laboratory research only; not for human or animal consumption.

Layer one: the receptor signal

The GHRH receptor is a seven-transmembrane G-protein-linked receptor found predominantly in the pituitary gland, essential for normal somatotroph proliferation and for the synthesis and secretion of GH (Gaylinn, 1999). Studies of chimeric receptors showed that the N-terminal extracellular domain is required for hormone binding, while key sites for ligand specificity and signaling lie in the transmembrane helices and intervening loops, and evidence from the ovine receptor suggests that the C-terminus has an inhibitory function and may be involved in down-regulation through internalization and phosphorylation (Gaylinn, 1999). The receptor belongs to the class B family and signals through Gs and cyclic AMP, the standard readout in receptor assays. Two consequences matter for any analog. First, receptor number sets a ceiling on response, so a cell line with high expression will exaggerate potency. Second, the possibility of internalization means that the duration of exposure is itself a variable that can change the subsequent response.

The analog differs from native GHRH in its backbone. The substitution pattern shared with the no-DAC form (D-Ala2, Gln8, Ala15 and a position-27 change) is described in the CJC-1295 (No DAC) research guide, and the rationale begins with the observation that plasma dipeptidylaminopeptidase cleaves GHRH at the N-terminus to give a product with less than one-thousandth of the biological activity (Frohman and colleagues, 1986).

Layer two: carrier-mediated persistence

In the original description, three maleimido derivatives of hGRF(1-29) were bioconjugated to human serum albumin ex vivo, and all three showed enhanced in vitro stability against dipeptidylpeptidase IV while remaining bioactive in cultured rat anterior pituitary cells (Jetté and colleagues, 2005). The design principle is that a reactive group on the peptide forms a covalent bond with the free thiol of Cys34 on serum albumin, so that after entering the bloodstream the peptide becomes part of an albumin complex. Kratz (2008) reviewed this approach, in which a peptide is bound covalently or physically to albumin to enhance its stability and half-life. The albumin half-life is itself the product of a recycling mechanism: the neonatal Fc receptor binds albumin and prolongs its lifespan, and in FcRn-deficient mice the albumin half-life is less than half that in wild-type mice (Chaudhury and colleagues, 2003).

LayerQuestion it answersWhat changes it
Receptor binding and signalingDoes the peptide activate the GHRH receptor and how strongly?Peptide sequence, receptor expression, assay system
Protease resistanceDoes the peptide survive plasma enzymes?N-terminal and internal substitutions
Albumin conjugationIs the peptide carried on albumin and for how long?The maleimide linker; albumin concentration and turnover
Feedback contextHow is the signal modified by endogenous regulators?Somatostatin tone, timing, IGF-1 feedback

Layer three: the feedback network that reads the signal

The receptor does not operate in isolation. Giustina and Veldhuis (1998) describe the GHRH/somatostatin–GH–IGF-I system as a multivalent feedback network that is sensitive to many neuroregulators and environmental stressors, with feedback and feedforward mechanisms acting within the intact somatotropic axis. A classic experiment shows how this plays out. Tannenbaum and Ling (1984) gave GRF peptides to freely moving male rats at the peak and the trough of the ultradian GH rhythm, and found that GH responses were significantly greater at the peak than at the trough. Immunoneutralization of somatostatin eliminated the difference, which supported the conclusion that the weak response at the trough was due to antagonism by endogenous circulating somatostatin. The practical meaning is that the response to a GHRH analog depends on when it is given relative to the animal’s own rhythm, not only on how much is given. This applies in principle to any analog and is the reason timing is a mandatory item in a study protocol.

For a long-persistence analog the timing logic changes. A short-acting peptide produces a defined pulse that the animal’s own somatostatin rhythm can shape. A peptide that remains available for days is present during both peak and trough phases, so the receptor sees a sustained stimulus against a changing background. What follows downstream depends on the endpoint chosen, and the published work reports this in measured terms rather than as a general conclusion.

What the knockout mouse study contributes

GHRH-knockout mice lack the endogenous hormone, so they provide a background in which the analog is the only GHRH-receptor ligand. In the 2006 study, 1-week-old knockout mice were exposed for 5 weeks with CJC-1295 at intervals of 24, 48 or 72 hours. The 24-hour group exhibited normal body weight and length; the 48- and 72-hour groups reached higher body weight and length than placebo without full normalization; relative lean mass and subcutaneous fat mass were normal in all exposed groups; and total pituitary RNA and GH mRNA increased, with immunohistochemistry consistent with somatotroph proliferation (Alba and colleagues, 2006). Two inferences are fair. The effect depends on the interval, which is what exposure persistence predicts. And the pituitary response includes a structural component, consistent with the established role of GHRH in somatotroph proliferation (Gaylinn, 1999).

Reading the knockout data as a table

Interval in the 2006 studyBody weight and lengthBody compositionPituitary read-out
24 hNormalRelative lean and subcutaneous fat mass normalTotal RNA and GH mRNA increased
48 hHigher than placebo, not fully normalizedRelative lean and subcutaneous fat mass normalTotal RNA and GH mRNA increased
72 hHigher than placebo, not fully normalizedRelative lean and subcutaneous fat mass normalTotal RNA and GH mRNA increased
Placebo (knockout)Reduced growthReferenceReference

The table restates the abstract and adds nothing beyond it. Its value is in showing that the pituitary read-outs were reported for the exposed groups collectively, while growth was graded by interval, so a reader cannot attribute the structural pituitary change to any single interval from the abstract alone. The full paper should be consulted for group-level detail before any such statement is made.

Distinguishing the layers experimentally

A laboratory that wants to attribute an observation to receptor signaling versus persistence can use a small set of comparisons.

  • Same backbone, with and without the linker. Comparing the DAC and no-DAC forms holds the peptide chain constant and varies persistence, the contrast explained in the DAC versus no-DAC comparison.
  • Albumin-free versus albumin-containing medium. In an albumin-free buffer the DAC cannot form its complex, so an in vitro potency difference between forms may reflect the medium, not the receptor.
  • cAMP kinetics. Measuring cAMP at several time points shows whether signaling is transient or sustained and whether desensitization appears.
  • Receptor internalization. Imaging or surface-binding assays show whether prolonged exposure reduces surface receptor.
  • Timing relative to the GH rhythm. In animals, recording the time of day and the dark cycle is required because the response varies with phase (Tannenbaum and Ling, 1984).
  • Somatostatin context. A somatostatin-pathway manipulation, where approved, tests how much of the response is limited by endogenous inhibition.

In practice this means that a mechanism statement should always name the layer it refers to. "CJC-1295 activates the GHRH receptor" is a statement about layer one; "CJC-1295 persists in the circulation" is a statement about layer two; and "CJC-1295 increases GH" is a statement about the whole system at a particular time, which depends on layer three. Keeping the layers separate prevents the most common reasoning error in this field, which is to explain a timing difference with a receptor argument or a receptor difference with a timing argument.

What is not established

The cited papers do not tell us how the complex behaves in species other than those studied, and they do not provide a complete account of receptor desensitization under sustained exposure. The albumin-conjugation literature establishes the principle; it does not by itself establish quantitative parameters for this particular peptide in any other system. Readers should also note that the 2005 and 2006 reports came from or with the sponsor developing the molecule. Related background is in the CJC-1295 DAC research overview, sermorelin for the unmodified fragment, and CJC-1295 vs sermorelin. V8 lists the no-DAC reagent as CJC-1295 (No DAC); the catalog shows the full range, and the COA library carries lot documentation where published.

For laboratory research use only.

Frequently asked questions

Is the DAC a separate pharmacological action?

No. It is a linker that attaches the peptide to albumin. The receptor action is the same GHRH receptor activation seen with other analogs; the DAC changes how long the peptide remains available.

What is the GHRH receptor?

A seven-transmembrane G-protein-linked receptor found mainly in the pituitary, essential for somatotroph proliferation and for GH synthesis and secretion.

How does the peptide attach to albumin?

A maleimide group on a lysine at the C-terminus reacts with the free thiol of Cys34 on serum albumin, forming a covalent bond.

Why does albumin extend persistence?

Albumin is abundant and long-lived, in part because the neonatal Fc receptor binds it and prolongs its half-life, so an attached peptide shares that persistence.

Does timing matter for the response to a GHRH analog?

Yes. In rats, GH responses to GRF were greater at the peak than at the trough of the GH rhythm, and somatostatin neutralization removed the difference.

What did the 2006 knockout mouse study report?

Once-daily administration normalized body weight and length in GHRH-knockout mice, less frequent intervals were less effective, and pituitary RNA and GH mRNA increased.

How can I tell receptor effects from persistence effects?

Compare the same backbone with and without the linker, run albumin-free and albumin-containing media, and measure cAMP and internalization over time.

Can internalization affect results?

Possibly. Evidence from the ovine receptor suggests the C-terminus may mediate down-regulation by internalization and phosphorylation, so exposure duration is a variable.

Does V8 supply the DAC form?

No. V8 lists the no-DAC form, and this article is a background explainer for laboratory readers.

Does this article give amounts or schedules?

No. It describes mechanism and design only, for laboratory research use.

Related reading: CJC-1295 DAC Pharmacokinetics: Half-Life Explained, CJC-1295 DAC Storage, Stock Math and Study Parameters, CJC-1295 DAC Safety Profile: Preclinical Tolerability.

References

  1. Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res. 1999;9(Suppl A):37-44. doi:10.1016/S1096-6374(99)80008-2
  2. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
  3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  4. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183. doi:10.1016/j.jconrel.2008.05.010
  5. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315-322. doi:10.1084/jem.20021829
  6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353
  7. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
  8. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.